Centene Corporation has recently been in the limelight due to a variety of reasons, highlighting its performance in both the stock market and business operations. There has been substantial insider trading, with the CEO, CFO and Directors' such as Christopher Coughlin, Thomas Greco, and H James Dallas making significant share purchases. Noteworthy financial reports have been released, including Q3 2024 results which surpassed estimates, and followed by the reaffirmation of the FY 2024 guidance. Furthermore, the corporation has published its 2025 profit guidance, appearing to be ahead of estimates. Stock analysts at UBS have upgraded their rating for the company from neutral to buy, indicating strong investor sentiments. However, despite strong financial performance and positive investor sentiments, the stock has seen moments of underperformance in the market. The company's subsidiary, Health Net, received recognition for its forward-thinking efforts, becoming the only health plan in the United States to receive the 'Health Equity Accreditation Plus' for 2024. In more corporate news, another subsidiary, Iowa Total Care, was awarded a statewide Medicaid contract. Despite these achievements, the company's Medicare 'star' rating was downgraded which resulted in a lawsuit against the US.
Centene Corporation CNC News Analytics from Thu, 07 Mar 2024 08:00:00 GMT to Fri, 20 Dec 2024 11:00:31 GMT -
Rating 6
- Innovation 5
- Information 8
- Rumor -1
